Erythritol
In clinical developmentAlso known as Erythro-tetritol, L-erythritol, Mesoerythritol, Phycite+6 more
Erythro-tetritol, L-erythritol, Mesoerythritol, Phycite, Phycitol, Erythrit, Erythrite, Erythrol, (2R,3S)-butane-1,2,3,4-tetrol, 1,2,3,4-butanetetrol.
Recent clinical, regulatory, research and industry developments relating to this drug.
Metabolic Effects of Selected Conventional and Alternative Sweeteners: A Narrative Review.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Journals, researchers & institutions
- Nutrients1
- Beglinger C1
- Bordier V1
- Meyer-Gerspach AC1
- Teysseire F1
- Wölnerhanssen BK1
- University of Basel1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across the same disease area as Erythritol in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials